Two facts about United Therapeutics sit side by side right now and refuse to make peace. The company has grown earnings per share from $11.54 in 2020 to $27.86 in 2025, a run that almost no pharmaceutical business sustains for half a decade. Yet the stock sits well below its 52-week high and has gone essentially nowhere in six months. The market’s current multiple embeds an assumption of slowing growth; the filed five-year record and 2026 pipeline events represent a different data set. Whether those two readings converge depends on outcomes the filings do not yet resolve.
That gap is what this audit is about. The math, what the filed numbers show, and the mood, what the current price implies, are in tension. Whether that tension resolves in favor of the filings or the market depends on pipeline and competitive outcomes that are not yet settled.
The quick read
United Therapeutics has compounded earnings at a pace most drug companies never achieve, and its margins have held above 41% for three straight years. The stock’s current price-to-earnings ratio sits at 17 times, only modestly above the company’s own decade median, which means the market is paying almost nothing for the pipeline bets management is making. The open question is whether a single soft quarter, driven by competition in one product, is a turning point or a speed bump, and the filed numbers do not yet answer that cleanly.
How a rare-disease specialist became a compounding machine
United Therapeutics built its business on one brutal disease: pulmonary arterial hypertension, a condition where the blood vessels feeding the lungs slowly stiffen until the heart gives out. For years the company had one main drug, Remodulin, delivered by a pump patients wear around the clock. That was a hard life for patients and a fragile foundation for a business.
The turning point came in May 2022, when the FDA approved Tyvaso DPI, an inhaled powder version of the company’s treprostinil molecule. Patients could breathe it in rather than carry a pump. Doctors prescribed it. Revenue followed: the 10-K for fiscal year 2025 shows Tyvaso DPI alone generating more than a billion dollars for the full year, roughly four of every ten dollars the company earned. That single approval transformed United Therapeutics from a niche infusion company into something closer to a franchise.
The five-year revenue arc reflects it. Sales more than doubled between 2020 and 2025, with net margins holding above 41% throughout the most recent three years. For context, keeping more than 41 cents of profit from every dollar of sales is unusual even among branded pharmaceutical companies, where 20 cents is considered healthy. The business has been extraordinarily efficient at turning revenue into earnings.
What the soft quarter actually shows
Then came the Q2 2026 10-Q, filed August 5. Total revenue of $783.3 million was down slightly from a year earlier, and management declined to update full-year guidance. That combination spooked the market. The stock is flat for six months.
But the quarter deserves a closer read. Nebulized Tyvaso, the older inhaled version, fell sharply year-over-year, squeezed by Liquidia Corporation’s Yutrepia, a competing inhaled powder approved in May 2025 that captured meaningful market share in its first half-year of sales. That competitive pressure is real. Remodulin, the original pump drug, also slipped as generic alternatives took share in the subcutaneous market. Neither of those trends is surprising given the competitive calendar.
What the mood is discounting is what grew. Tyvaso DPI, the franchise product, rose in the quarter, helped by both volume gains and a price increase. Orenitram, an oral therapy, held essentially flat while maintaining record patient numbers. The business is not shrinking uniformly. Two legacy products are losing ground to competition; the flagship product is still growing. Those are different stories wearing the same quarterly headline.
The pipeline the price is ignoring
Here is where the pessimism audit gets interesting. A stock priced at a median multiple is typically associated with a median pipeline. The filed 2026 pipeline events, FDA acceptances, Phase 3 readouts, represent a more active set of binary outcomes than the multiple alone would suggest. Whether those outcomes are favorable is not yet determinable from the filings.
In March 2026, the company announced Phase 3 results showing ralinepag, an oral pill for pulmonary arterial hypertension, cut the risk of clinical worsening by more than half compared to placebo, according to the press release filed that month. The FDA accepted the New Drug Application for ralinepag on August 24, 2026, setting a review deadline in mid-2027. Management said on the August earnings call that ralinepag could double the addressable PAH patient population after launch, because it reaches patients who cannot tolerate or access injectable or inhaled therapies.
Separately, positive Phase 3 data from the TETON-1 and TETON-2 trials, presented in May 2026, showed nebulized Tyvaso improved lung function meaningfully in idiopathic pulmonary fibrosis, a progressive scarring disease with far more patients than PAH. The company submitted the supplemental application to the FDA by late summer 2026. IPF is a large and underserved market. If approved, it would be the first time Tyvaso competes outside the pulmonary hypertension category entirely.
Management has stated a target of a $4 billion annual revenue run rate by the end of 2027, driven by these new indications. We cannot validate that figure independently from filed numbers, and BullScope’s framework does not produce forward ranges for this name. But the pipeline events themselves, the FDA acceptances and the Phase 3 readouts, are filed and dated facts, not projections.
The balance sheet as a second opinion
A company facing genuine decline typically shows it in the balance sheet first: cash shrinks, debt grows, buybacks get suspended. United Therapeutics shows the opposite. As of June 30, 2026, the company held $3.8 billion in cash and investments, per the Q2 10-Q, against short-term debt that had fallen to a negligible level, down from a substantial balance a year earlier. That is a balance sheet that says the business generates more cash than it needs to run itself.
In March 2026, the board authorized a large share repurchase program. The company immediately deployed most of it through accelerated agreements, buying back millions of shares in a single quarter. A business that fears its own future does not typically hand that much capital back to shareholders all at once. The Thymmune Therapeutics acquisition in July 2026, structured with an upfront payment and contingent milestones, adds a regenerative medicine angle without straining the cash position in any meaningful way.
What the valuation embeds
Our data shows the stock trading at 17 times trailing earnings, against the company’s own decade median of 15.6 times. That puts the multiple modestly above its own history, which sounds elevated until you consider what the history contains: years when the pipeline was thinner, the product mix was narrower, and the balance sheet carried more debt. On price-to-sales, the stock sits at the 89th percentile of its own decade range, which is the more cautious signal.
The tension is this: a multiple near the historical median implies the market expects roughly median growth. But the filed five-year record, and the pipeline events of 2026, represent an above-median setup. The multiple sits near its historical median; the filed pipeline activity in 2026 represents a more active setup than several prior years at that same median. Whether the pipeline converts that activity into earnings is the condition the multiple has not yet priced in either direction.
Published analyst estimates as of August 2026, per Stock Analysis, ranged from roughly $515 to $677, a spread of more than $160 that reflects the same unresolved pipeline question the filed numbers surface. BullScope does not adopt or endorse any of those figures; they are cited to illustrate the breadth of current analytical disagreement.
Reading the numbers
- Revenue growth, FY2020 to FY2025: Sales rose from $1.5 billion to $3.2 billion over five years, per the FY2025 10-K. What it means: the business more than doubled in size without an acquisition driving the headline. Why it matters: sustained organic growth at this pace is rare in specialty pharma, where one patent expiry can erase years of gains. Worked example: a company earning $100 in year one that grows at this pace earns roughly $213 by year five.
- Net margin, FY2023 to FY2025: 42.3%, 41.5%, 41.9%: The operating margin, meaning what’s left of each dollar of sales after all the bills, has held in a tight band across three consecutive years, per the FY2025 10-K and FY2023 10-K. What it means: the business is not sacrificing profitability to buy growth. Why it matters: many drug companies see margins compress as they invest in new products. United Therapeutics has not. Worked example: a restaurant keeping 42 cents of every dollar of food sold, year after year, while opening new locations, is doing something structurally right.
- Q2 2026 revenue, $783.3 million, down 2%: Filed in the Q2 2026 10-Q. What it means: the first year-over-year revenue decline in recent memory. Why it matters: it is the single data point the market is pricing most heavily. Worked example: a shop that grew sales every year for five years and then had one quarter where sales dipped 2% is not obviously in trouble, but it is worth watching the next quarter carefully.
- Cash and investments, $3.8 billion as of June 30, 2026: Per the Q2 2026 10-Q. What it means: the company holds more cash than it earns in an entire year of revenue. Why it matters: that cushion funds the pipeline, the buybacks, and the acquisitions without requiring debt. Worked example: a household earning $80,000 a year with $100,000 in savings has options that a household with $5,000 in savings does not.
- P/E of 17 times vs. decade median of 15.6 times (our data): What it means: the market is paying a modest premium to the company’s own historical average. Why it matters: a stock priced at its median multiple is not pricing in much growth, which is unusual when the pipeline is as active as it is right now. Worked example: if a coffee shop typically sells for 15 times its annual profit and today sells for 17 times, the buyer is paying a small premium but is not betting on explosive growth.
Sources
- UTHR 10-Q, Q2 2026 (SEC EDGAR)
- UTHR 10-K, FY2025 (SEC EDGAR)
- UTHR 10-K, FY2023 (SEC EDGAR)
- United Therapeutics Q2 2026 earnings press release
- Ralinepag Phase 3 ADVANCE OUTCOMES results, March 2026
- FDA ralinepag NDA acceptance, August 2026
- UTHR Q2 2026 earnings call transcript (Motley Fool)
- UTHR analyst price targets (Stock Analysis)
- Tyvaso DPI FDA approval, May 2022
